PPT-HER2 positive breast carcinoma in the pre and post adjuvant anti-HER-2 therapy era: a

Heather M Gage MD Avanti Rangnekar Robert E Heidel PhD Timothy Panella MD John Bell MD and Amila Orucevic MD PhD The Graduate School of Medicine The Department of Pathology Introduction. Clinical Practice Guideline Update. American Society of Clinical Oncology /. College of American Pathologists . www.asco.org/guidelines/. © American . Society of Clinical Oncology®.  All rights reserved.. First . Line and Beyond. Moderator:. Joseph Gligorov, MD, . PhD . Head, Cancer . Coordination Center . HUEP. University . Cancer . Institute. Sorbonne University. Paris. , . France. Panelist:. Carlos H. Barrios, . Joyce O'Shaughnessy, MD. Kimberly Blackwell, MD. Hope . Rugo. , MD. Reminder: feedback is appreciated. You will be prompted at the end for your feedback.. Updates on Chemotherapy and Other Novel Agents. Jennifer M. Matro, MD. Rena Rowan Breast Center. Abramson Cancer Center. University of Pennsylvania. Overview. What is metastatic breast . c. ancer (MBC)?. Who is at risk?. Subtypes of Breast Cancer. Dr. . Khaled Abulkhair, PhD. Medical Oncology SCE, Royal College, UK. Ass. Professor of Clinical Oncology. Mansoura University, Egypt. A long Road Searching for optimum Neo-Adjuvant Therapy in Her -2 Positive Breast Cancer. Management of HER2 Over-Expressed Breast Cancer in the Adjuvant, Neoadjuvant, and Metastatic settings Christy A Russell, MD Keck School of Medicine University of Southern California Metastatic Breast Cancer What is the evidence for adjuvant chemotherapy?. Do patients achieving a pathological complete response need chemotherapy?. How do we incorporate . Oxaliplatin. following the recent data from ASCO 2014?. Department. of . oncology. . UWM. Epidemiology. Breast cancer is the most common malignancy in women in the United States and is second only to lung cancer as a cause of cancer death. . The American Cancer Society has estimated that 279,100 Americans will be diagnosed with breast cancer and 42,690 will die of disease in the United States in 202. Presented by:. Dr. . Iram. Naseer. Moderated by:. Prof .. Iqbal. Aziz. . BREAST CARCINOMA. •Breast cancer is most . common. malignancy . in . female. . •Second to lung . cancer. •Now the mortality rate . Professor of Medicine and Oncology. Karmanos Cancer Institute. Wayne State University. Breast Cancer 101. Biopsy +. Lumpectomy + RT. Mastectomy. SLNBx. ALND (> 3+ micro or macro preop and bx +). Standard, . Most of these lesions are benign. Breast cancer is 2. nd. most common cause of cancer deaths in women, following. carcinoma of the lung. . The clinical significance of the . benign. conditions:. 1- possible clinical confusion with malignancy. in Development for . Breast Cancer. Sara A. Hurvitz, MD, FACP. Professor of Medicine. David Geffen School of Medicine, UCLA. Los Angeles, CA. William J. Gradishar, MD, FASCO, FACP. Betsy Bramsen Professor of Breast Oncology & Professor of Medicine. Anne Sofie Brems-Eskildsen. Department of Oncology, University Hospital of Aarhus. Guidelines in . Oncology . for ILC follows IDC. ASCO . G. uidelines . for early breast cancer (not mentioned). St. . . Bidstrup. Mrs B is a 49 . yo. woman who attended for a regular 3 weekly review and Herceptin dose. Intro. Dec 2000: . attended GP regarding lump that had been present in L) breast for 6/12. . Bx. - breast ca.